{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:44:12Z","timestamp":1790113452706,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.neo.2024.101073","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T20:29:05Z","timestamp":1729369745000},"page":"101073","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Specifying the choice of EGFR-TKI based on brain metastatic status for advanced NSCLC with EGFR p.L861Q mutation"],"prefix":"10.1016","volume":"58","author":[{"given":"Lan-Lan","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Tao","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Di","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Feng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.neo.2024.101073_bib0001","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S1470-2045(09)70110-X","article-title":"EGFR testing in lung cancer is ready for prime time","volume":"10","author":"Hirsch","year":"2009","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.neo.2024.101073_bib0002","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrc.2016.56","article-title":"Biomarker development in the precision medicine era: lung cancer as a case study","volume":"16","author":"Vargas","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.neo.2024.101073_bib0003","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ccell.2020.09.008","article-title":"Driving the improvement of lung cancer prognosis","volume":"38","author":"Liang","year":"2020","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.neo.2024.101073_bib0004","first-page":"156","article-title":"Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer","volume":"4","author":"Kohno","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"issue":"2","key":"10.1016\/j.neo.2024.101073_bib0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.neo.2024.101073_bib0006","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.2010.33.4235","article-title":"Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)","volume":"29","author":"Fukuoka","year":"2011","journal-title":"J. Clin. Oncol"},{"issue":"2","key":"10.1016\/j.neo.2024.101073_bib0007","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.neo.2024.101073_bib0008","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"Harrison","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"4","key":"10.1016\/j.neo.2024.101073_bib0009","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/oncolo\/oyac022","article-title":"Tyrosine kinase inhibitor activity in patients with NSCLC harboring uncommon EGFR mutations: a retrospective international cohort study (UpSwinG)","volume":"27","author":"Popat","year":"2022","journal-title":"Oncologist."},{"key":"10.1016\/j.neo.2024.101073_bib0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.lungcan.2016.01.018","article-title":"EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: a real-world study in China","volume":"96","author":"Xu","year":"2016","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.neo.2024.101073_bib0011","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/cas.12996","article-title":"Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy","volume":"107","author":"Kobayashi","year":"2016","journal-title":"Cancer Sci."},{"issue":"6","key":"10.1016\/j.neo.2024.101073_bib0012","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1016\/j.apsb.2023.03.007","article-title":"Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations","volume":"13","author":"Shi","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.neo.2024.101073_bib0013","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jtho.2020.09.019","article-title":"Allele-specific role of ERBB2 in the oncogenic function of EGFR L861Q in EGFR-Mutant Lung Cancers","volume":"16","author":"Sato","year":"2021","journal-title":"J. Thoracic Oncol"},{"issue":"8","key":"10.1016\/j.neo.2024.101073_bib0014","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.21037\/tcr-23-95","article-title":"The treatment of patients with non-small cell lung cancer carrying uncommon EGFR mutations, HER2 mutations, or brain metastases: a systematic review of pre-clinical and clinical findings for dacomitinib","volume":"12","author":"Yang","year":"2023","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.neo.2024.101073_bib0015","article-title":"EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors","volume":"13","author":"Xu","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"7878","key":"10.1016\/j.neo.2024.101073_bib0016","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.neo.2024.101073_bib0017","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.neo.2024.101073_bib0018","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.19.00931","article-title":"Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09)","volume":"38","author":"Cho","year":"2020","journal-title":"J. Clin. Oncol"},{"issue":"2","key":"10.1016\/j.neo.2024.101073_bib0019","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11060-017-2590-x","article-title":"High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases","volume":"135","author":"Ge","year":"2017","journal-title":"J. Neurooncol."},{"issue":"3","key":"10.1016\/j.neo.2024.101073_bib0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.1617","article-title":"Assessment of effectiveness and safety of osimertinib for patients with intracranial metastatic disease: a systematic review and meta-analysis","volume":"3","author":"Erickson","year":"2020","journal-title":"JAMa Netw. Open."},{"issue":"1","key":"10.1016\/j.neo.2024.101073_bib0021","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12916-023-02865-z","article-title":"Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies","volume":"21","author":"Hu","year":"2023","journal-title":"BM Med."},{"issue":"12","key":"10.1016\/j.neo.2024.101073_bib0022","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1158\/1078-0432.CCR-23-3302","article-title":"Co-occurring EGFR p.E709X mutation mediates primary resistance to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC","volume":"30","author":"Pang","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.neo.2024.101073_bib0023","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.annonc.2022.02.225","article-title":"Treatment outcome of atypical EGFR mutations in the German national network genomic medicine lung cancer (nNGM)","volume":"33","author":"Janning","year":"2022","journal-title":"Annal. Oncol"},{"issue":"5","key":"10.1016\/j.neo.2024.101073_bib0024","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/JTO.0000000000000504","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X\/L861Q\/S768I mutations","volume":"10","author":"Chiu","year":"2015","journal-title":"J. Thoracic Oncol"},{"issue":"11","key":"10.1016\/j.neo.2024.101073_bib0025","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-10-3408","article-title":"Effectiveness of tyrosine kinase inhibitors on \"uncommon\" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer","volume":"17","author":"Wu","year":"2011","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.neo.2024.101073_bib0026","article-title":"Afatinib for the treatment of non-small cell lung cancer harboring uncommon EGFR mutations: an updated database of 1023 cases brief report","volume":"12","author":"Yang","year":"2022","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.neo.2024.101073_bib0027","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11523-023-00946-w","article-title":"Afatinib in untreated stage IIIB\/IV lung adenocarcinoma with major uncommon epidermal growth factor receptor (EGFR) mutations (G719X\/L861Q\/S768I): a multicenter observational study in Taiwan","volume":"18","author":"Hsu","year":"2023","journal-title":"Target Oncol."},{"issue":"6","key":"10.1016\/j.neo.2024.101073_bib0028","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1111\/cas.15769","article-title":"Real-world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: a multi-center study","volume":"114","author":"Qin","year":"2023","journal-title":"Cancer Sci."},{"issue":"2","key":"10.1016\/j.neo.2024.101073_bib0029","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jtho.2022.10.004","article-title":"UNcommon EGFR mutations: international case series on efficacy of osimertinib in real-life practice in first-line setting (UNICORN)","volume":"18","author":"Bar","year":"2023","journal-title":"J. Thoracic Oncol"},{"issue":"3","key":"10.1016\/j.neo.2024.101073_bib0030","article-title":"Osimertinib in NSCLC with atypical EGFR-activating mutations: a retrospective multicenter study","volume":"4","author":"Ji","year":"2023","journal-title":"JTo Clin. Res. Rep."},{"issue":"9, Supplement","key":"10.1016\/j.neo.2024.101073_bib0031","doi-asserted-by":"crossref","first-page":"S418","DOI":"10.1016\/j.jtho.2022.07.728","article-title":"EP08.02-046 activity of OsimeRTInib in NSCLC with uncommon EGFR mutations: retrospective observational multicenter study (ARTICUNO)","volume":"17","author":"Pizzutilo","year":"2022","journal-title":"J. Thoracic Oncol"},{"issue":"21","key":"10.1016\/j.neo.2024.101073_bib0032","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1002\/cncr.34451","article-title":"Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X\/L861Q\/S768I","volume":"128","author":"Pang","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.neo.2024.101073_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.999606","article-title":"Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation","volume":"12","author":"Dong","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.neo.2024.101073_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.709877","article-title":"Afatinib in EGFR TKI-Na\u00efve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies","volume":"11","author":"Passaro","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.neo.2024.101073_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2024.03.016","article-title":"Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review","author":"Borgeaud","year":"2024","journal-title":"J. Thoracic Oncol"},{"issue":"2","key":"10.1016\/j.neo.2024.101073_bib0036","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/annonc\/mdw611","article-title":"Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial","volume":"28","author":"Paz-Ares","year":"2017","journal-title":"Annals Oncol."},{"issue":"27","key":"10.1016\/j.neo.2024.101073_bib0037","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1200\/JCO.21.02641","article-title":"AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations","volume":"40","author":"Lu","year":"2022","journal-title":"J. Clin. Oncol"},{"issue":"11","key":"10.1016\/j.neo.2024.101073_bib0038","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","article-title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir. Med."}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558624001143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558624001143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T20:48:44Z","timestamp":1731012524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558624001143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":38,"alternative-id":["S1476558624001143"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2024.101073","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Specifying the choice of EGFR-TKI based on brain metastatic status for advanced NSCLC with EGFR p.L861Q mutation","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2024.101073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101073"}}